Evaluation and Treatment of Gender Dysphoria to Prepare for Gender Confirmation Surgery

    June 2018 in “ Sexual Medicine Reviews ”
    Miriam Hadj-Moussa, Dana A. Ohl, William M. Kuzon
    Image of study
    TLDR The document concludes that non-operative treatment for gender dysphoria is safe and effective, and hormone therapy does not increase cancer risk.
    The document from October 1, 2018, provides a comprehensive review of the evaluation and treatment of gender dysphoria, particularly focusing on non-operative and operative treatments to prepare patients for gender confirmation surgery (GCS). It emphasizes the need for individualized, multidisciplinary care, including psychotherapy, social gender transition, and cross-sex hormone therapy, following the guidelines of the World Professional Association for Transgender Health (WPATH) and the Endocrine Society (ES). The document notes an increase in patients seeking treatment for gender dysphoria and a lack of experienced physicians. It outlines the benefits of hormone therapy, such as relief from dysphoria and improved quality of life, and discusses eligibility criteria for hormone therapy, including informed consent and management of comorbidities. The document also addresses the phenotypic effects of hormone therapy, such as changes in hair growth and distribution, and the safety profile of testosterone and estrogen therapy, including the risks of polycythemia and venous thromboembolism (VTE), respectively. It concludes that non-operative treatment is generally safe and effective, and that there is no increased risk of cancer associated with hormone therapy for transgender individuals. The document is part of a series, with subsequent parts focusing on the surgical aspects of gender dysphoria treatment.
    Discuss this study in the Community →

    Research cited in this study

    4 / 4 results

    Related Community Posts Join

    6 / 113 results

      community Dependency on Minoxidil - what to do?

      in Transgender  1 upvotes 1 year ago
      The individual is using oral minoxidil and finasteride to treat androgenetic alopecia with good results but is considering stopping due to concerns about long-term effects on the heart and potential hair dependency on the medication. They are also contemplating the impact of hair loss on gender dysphoria and considering the use of wigs as an alternative.

      community 2.5 years Minoxidil and HRT, CPA->Lupron +Minox 5%

      in Transgender  611 upvotes 1 month ago
      The user experienced significant hair regrowth after 2.5 years of using Minoxidil 5% and hormone replacement therapy (HRT) with Lupron, despite initial scalp irritation. Finasteride was ineffective for them.

      community Well… I Did It. Estrogen Saved My Hairline

      in Transgender  717 upvotes 3 months ago
      OP transitioned and used Spironolactone, Estradiol Valerate, Minoxidil, and dermarolling, resulting in significant hair regrowth. They advise this method may not be suitable for cis men.

      community Progress: 1 year mtf hrt, 9 months Min/Fin

      in Transgender  116 upvotes 3 weeks ago
      The user experienced significant hair regrowth after one year on male-to-female hormone replacement therapy (HRT) and nine months using minoxidil and finasteride. They noted a reduction in body hair and attributed much of the hair regrowth to the addition of minoxidil.

      community Found the solution tressbros - 1.5 years 2.5mg oral minox, 5mg finasteride, 8mg estradiol valerate (weekly)

      in Transgender  591 upvotes 10 months ago
      The conversation discusses a transgender individual's successful hair loss treatment over 1.5 years using 2.5mg oral minoxidil, 5mg finasteride, and 8mg weekly injectable estradiol valerate. Some users debate the appropriateness of this approach within the group's goals, while others support the individualized treatment and its additional benefits for transgender individuals.

    Related Research

    1 / 1 results